Abbott Laboratories (NYSE: ABT), a leading US healthcare company, has announced the opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland. This new site, which serves as a global manufacturing center of excellence for Abbott’s diabetes care business, is expected to create over 800 new jobs.
Details of the Kilkenny Facility and Investment
The Kilkenny facility is part of Abbott’s EUR 440 million (USD 607.7 million) investment in Ireland, which also includes a significant expansion of the company’s Donegal site, adding 200 new jobs. The new 30,000-square meter Kilkenny facility will manufacture FreeStyle Libre 3 sensors, the world’s smallest and latest generation in Abbott’s continuous glucose monitoring portfolio, designed for people living with diabetes.
European Expansion and Additional Investments
Beyond Ireland, Abbott is increasing its manufacturing capacity in Europe with an additional EUR 85 million (USD 117.4 million) investment in its Witney facility in Oxfordshire, UK. This investment underscores Abbott’s commitment to enhancing its production capabilities and supporting the growing needs of the diabetes community across the region.-Fineline Info & Tech
Leave a Reply